Treatment of Obese Subjects with the Oral Growth Hormone Secretagogue MK-677 Affects Serum Concentrations of Several Lipoproteins, But Not Lipoprotein(a)1
| Autor: | John-Olov Jansson, Olov Wiklund, Marja-Riitta Taskinen, Johan Svensson, Bengt-Åke Bengtsson, Gudmundur Johannsson, Malin Ottosson |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Apolipoprotein E
medicine.medical_specialty Apolipoprotein B Cholesterol Endocrinology Diabetes and Metabolism Biochemistry (medical) Clinical Biochemistry Lipoprotein(a) Biology Placebo Biochemistry Growth hormone secretion chemistry.chemical_compound Endocrinology chemistry Internal medicine Low-density lipoprotein medicine biology.protein lipids (amino acids peptides and proteins) Lipoprotein |
| Zdroj: | The Journal of Clinical Endocrinology & Metabolism. 84:2028-2033 |
| ISSN: | 1945-7197 0021-972X |
| DOI: | 10.1210/jcem.84.6.5799 |
| Popis: | Obesity is associated with blunted GH secretion and an unfavorable lipoprotein pattern. The objective of this study was to investigate the effects of treatment with the oral GH secretagogue MK-677 on lipoproteins in otherwise healthy obese males. The study was randomized, double blind, and parallel. Twenty-four obese males, aged 18–50 yr, with body mass index greater than 30 kg/m2 and waist/hip ratio above 0.95 were treated with 25 mg MK-677 (n = 12) or placebo (n = 12) daily for 8 weeks.MK-677 treatment did not significantly change serum lipoprotein(a) [Lp(a)] levels. Serum apolipoprotein A-I and E (apoA-I and apoE) were increased at 2 weeks (P < 0.001 and P < 0.01 vs. placebo, respectively), but were not changed at study end. Serum total cholesterol and low density lipoprotein (LDL) cholesterol (LDL-C) levels were not significantly changed by MK-677 treatment. Serum high density lipoprotein (HDL) cholesterol (HDL-C) was increased at 2 weeks of MK-677 treatment (P < 0.01 vs. placebo), but not at 8 weeks. The LDL-C/HDL-C ratio was reduced after 8 weeks of MK-677 treatment (P < 0.05 vs. placebo). Mean LDL particle diameter was decreased at 2 weeks (P < 0.05 vs. placebo), but was unchanged compared with baseline values at 8 weeks (P = NS vs. placebo). The level of serum triglycerides was increased at 2 (P < 0.05 vs. placebo), but not at 8, weeks. Lipoprotein lipase activity in abdominal and gluteal sc adipose tissue was not affected by active treatment.In conclusion, treatment with the oral GH secretagogue MK-677 affected circulating lipoproteins. The effects on serum apoA-1, apoE, triglycerides, and mean LDL particle diameter were transient. At study end, the LDL-C/HDL-C ratio was decreased. MK-677 treatment did not significantly affect serum Lp(a) concentrations at the present dose and administration protocol. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|